Junshi Bio's TIL Therapy Nojilence (GC101) Becomes First TIL in China to Have Filing Accepted

Junshi Bio's autologous TIL therapy nojilence (GC101), developed on the DeepTIL cell enrichment and expansion platform, has had its marketing application accepted, making it the first TIL therapy to reach this stage in China. Per the materials, the therapy requires no high-intensity lymphodepletion chemotherapy and no IL-2 administration. Grade ≥3 TEAEs were mainly hematologic toxicity from preconditioning, with a median duration of 8 days versus 13 days in the chemotherapy control group, and no TIL treatment-related adverse events occurred during extended follow-up.